Biotech Most Active: ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP), Gilead Sciences Inc. (NASDAQ:GILD), Regado Biosciences, Inc. (NASDAQ:RGDO)

Biotech Most Active: ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP), Gilead Sciences Inc. (NASDAQ:GILD), Regado Biosciences, Inc. (NASDAQ:RGDO)

Intrexon Corporation (XON), a leader in synthetic biology and its oncology partner, ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) [Trend Analysis] announced a broad exclusive licensing agreement with The University of Texas MD Anderson Cancer Center, including an exclusive sublicensing agreement through MD Anderson for intellectual property developed at the University of Minnesota for the development of non-viral adoptive cellular cancer immunotherapies. ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) finished at $8.87 as shares increasing 54.53%. As took noticed on the firm performance, its weekly performance was 76.69%, monthly performance was 104.85%. The stock price of ZIOP is moving up from its 20 days moving average with 81.07% and isolated positively from 50 days moving average with 111.66%.

In a setback for Gilead Sciences Inc. (NASDAQ:GILD) [Trend Analysis] +2.11%, India’s patent office has rejected an application for its Sovaldi hepatitis C treatment. The decision means that locally-based drug makers can sell lower-cost generic versions of the medicine, which costs $1,000-a-day in the U.S. for a 12-week regimen. The patent application had been opposed by Natco Pharma 524816.BY +4.51%, an Indian generic drug maker, and the Initiative for Medicines, Access & Knowledge, a non-profit. Gilead Sciences Inc. (NASDAQ:GILD) stock finished trading at $99.26 in last trading day with market capitalization of 149.8 Billion. The stock has a 52-week high price of $116.83 and its 52-week low was recorded at $63.50.

Regado Biosciences, Inc. (NASDAQ:RGDO) [Trend Analysis] (RGDO) and Tobira Therapeutics, Inc. today announced that they have entered into a definitive agreement under which privately-held Tobira will merge with a wholly-owned subsidiary of Regado in an all-stock transaction. The merger will create a company focused on the development of novel treatments for liver and inflammatory diseases. Tobira’s lead product, immunomodulator and anti-fibrotic agent cenicriviroc (CVC), received Fast Track Designation and is currently in a Phase 2b trial in non-alcoholic steatohepatitis (NASH). Upon closing of the transaction, Regado will be renamed Tobira Therapeutics, Inc., and will be under the leadership of Tobira’s chief executive officer, Laurent Fischer, M.D. Regado Biosciences, Inc. (NASDAQ:RGDO) surged 17.44% to settle at $1.01 with the total traded volume of 8.3 Million shares. The company’s shares performance for the last one month was 13.48% and 12.22% in the previous week, whereas year to date performance was calculated 10.99%.